CytoDyn Inc. (OTCMKTS:CYDY) Short Interest Update

CytoDyn Inc. (OTCMKTS:CYDY) was the target of a significant increase in short interest in October. As of October 31st, there was short interest totalling 16,577,600 shares, an increase of 25.8% from the October 15th total of 13,179,400 shares. Based on an average daily volume of 6,265,900 shares, the short-interest ratio is currently 2.6 days.

CytoDyn Stock Performance

CYDY stock remained flat at $0.12 during trading on Friday. 2,795,684 shares of the company were exchanged, compared to its average volume of 2,584,065. CytoDyn has a one year low of $0.11 and a one year high of $0.42. The firm has a market cap of $149.98 million, a P/E ratio of -6.06 and a beta of 0.17. The business has a fifty day simple moving average of $0.14 and a 200-day simple moving average of $0.15.

CytoDyn (OTCMKTS:CYDY) last announced its quarterly earnings data on Tuesday, October 15th. The biotechnology company reported $0.02 earnings per share for the quarter.

CytoDyn Company Profile

CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.